Technical Analysis for DFFN - Diffusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 0.695 -6.71% -0.05
DFFN closed down 6.71 percent on Thursday, April 15, 2021, on 19 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical DFFN trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -6.71%
Wide Bands Range Expansion -6.71%
Older End-of-Day Signals for DFFN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 17 hours ago
Lower Bollinger Band Support about 18 hours ago
Down 3% about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 2 % about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Diffusion Pharmaceuticals Inc. Description

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Oncology Cancer Treatments Chemotherapy Radiation Macular Degeneration Ophthalmology Blastoma Oxygen Cancer Cell Dermatology Glioblastoma Radiation Therapy Acne Signal Transduction Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris Pi3k/Akt/Mtor Pathway

Is DFFN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.85
52 Week Low 0.4012
Average Volume 8,450,465
200-Day Moving Average 0.96
50-Day Moving Average 1.06
20-Day Moving Average 0.90
10-Day Moving Average 0.83
Average True Range 0.08
ADX 31.31
+DI 10.33
-DI 34.79
Chandelier Exit (Long, 3 ATRs ) 0.88
Chandelier Exit (Short, 3 ATRs ) 0.92
Upper Bollinger Band 1.10
Lower Bollinger Band 0.69
Percent B (%b) 0.0
BandWidth 45.07
MACD Line -0.08
MACD Signal Line -0.07
MACD Histogram -0.0146
Fundamentals Value
Market Cap 44.49 Million
Num Shares 64 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -0.14
Price-to-Sales 0.00
Price-to-Book 1.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.84
Resistance 3 (R3) 0.85 0.81 0.82
Resistance 2 (R2) 0.81 0.78 0.81 0.81
Resistance 1 (R1) 0.75 0.76 0.74 0.74 0.80
Pivot Point 0.72 0.72 0.71 0.71 0.72
Support 1 (S1) 0.66 0.68 0.64 0.65 0.59
Support 2 (S2) 0.62 0.66 0.62 0.58
Support 3 (S3) 0.56 0.62 0.57
Support 4 (S4) 0.55